Participants
hypersensitivity
ONCOLOGY, HYPERSENSITIVITY, METASTASES, IMMUNODEFICIENCY
Eligible patients had mCRPC with metastases and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, adequate organ function, no known hypersensitivity to vaccines or components of the cell therapy, and no contraindications to surgery (Supplementary S1B). The exclusion criteria contained immunodeficiency, other active malignancy, and recent or ongoing anti-tumor treatment. Prior radiotherapy and treatment with androgen deprivation and androgen receptor targeting drugs were accepted (Supplementary S1C).